Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 25, 2022

Sapanisertib Plus Fulvestrant in Women With Advanced Breast Cancer After Progression on Aromatase Inhibitor

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Clin. Cancer Res 2022 Jan 03;[EPub Ahead of Print], JÁ García-Sáenz, N Martínez-Jáñez, R Cubedo, Y Jerez, A Lahuerta, S González-Santiago, N Ferrer, M Ramos, JL Alonso-Romero, A Antón, E Carrasco, J Chen, R Neuwirth, K Galinsky, S Vincent, EJ Leonard, D Slamon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading